PALB2 and triple-negative breast carcinoma: Most previous studies have not found evidence that PALB2 mutations were associated with hormone-receptor negative breast tumours [16]–[18], [42], but one study reported that carriers of a Finnish founder mutation in PALB2 had triple negative breast cancer significantly more often than other breast cancer patients [43].